SCHEMBL26984883

SCHEMBL26984883

COc1cc(Cc2cncc(Nc3ccc(Cl)cc3F)c2C)ccc1NC(=O)OC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P2RX3 P56373 2/20 0.40
▸ NUDT1 P36639 4/20 0.39
▸ FPR1 P21462 1/20 0.38
▸ CSF1R P07333 1/20 0.38
▸ ACVR1B P36896 2/20 0.37
▸ TGFBR1 P36897 2/20 0.37
▸ ACVRL1 P37023 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ MTNR1A P48039 1/20 0.37
▸ MTNR1B P49286 1/20 0.37
▸ PTGER1 P34995 2/20 0.36
▸ EGFR P00533 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ CYP17A1 P05093 1/20 0.36
▸ FLT1 P17948 3/20 0.36
▸ KDR P35968 3/20 0.36
▸ FGFR1 P11362 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30746601 1.00 P2RX3 (0.40) P2RX3NUDT1FPR1CSF1RACVR1B
SCHEMBL26985170 0.81 ALDH1A1 (0.42) NUDT1FPR1CSF1REGFRFLT1
SCHEMBL30746656 0.81 ALDH1A1 (0.42) NUDT1FPR1CSF1REGFRFLT1
SCHEMBL26985148 0.81 EGFR (0.39) NUDT1FPR1CSF1RMAPTEGFR
SCHEMBL30746620 0.81 EGFR (0.39) NUDT1FPR1CSF1RMAPTEGFR
SCHEMBL4118124 0.73 LPAR1 (0.52) MEN1MAPTKMT2AEGFRKDR
SCHEMBL26985070 0.73 NUDT1 (0.40) NUDT1CSF1RACVR1BTGFBR1ACVRL1
SCHEMBL26984830 0.73 KDM4C (0.35) NUDT1ACVR1BTGFBR1ACVRL1MEN1
SCHEMBL17616117 0.72 KMT2A (0.52) MEN1MAPTKMT2AL3MBTL1CYP17A1
SCHEMBL30746528 0.71 NUDT1 (0.47) NUDT1CSF1RMEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001845-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS INC (US) 2026-01-01 — — US disclosed
US-20250288571-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS, INC. 2025-09-18 — — US disclosed
WO-2024010925-A2 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS, INC. (US) 2024-01-11 — — WO disclosed
WO-2024010925-A2 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS, INC. (US) 2024-01-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001845-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS MAPK6, MAPK3, MAPK1 P2RX3 2053/4885NUDT1 1810/4885FPR1 2098/4885
US-20250288571-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS BRAF, MAP3K1, MAP3K5 P2RX3 3345/4885NUDT1 2559/4885FPR1 2492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback